Acute respiratory distress syndrome (ARDS) is often fatal and very difficult to treat. Ventilation, fluids, anti-inflammatories, diuretics, antibiotics are used as supportive care for decades.

Preclinical Animal Models of Covid-Ards at CBI.

We at CBI have decades of experience in infectious, sepsis, and inflammatory models, including pulmonary and systemic inflammation. Our CEO, Dr. Carol Meschter, had worked for a number of years at Hoffmann LaRoche and then in biotech in Silicon Valley on Sepsis teams, with various inhibitors such as humanized anti-TAC, anti-TNF fusion proteins, interleukins, PAF antagonists, stem cells and anti-infectives.

For the past year, we at CBI have been developing and implementing rodent models of COVID-ARDS in order to evaluate potential new treatments for our clients.

HOW CAN CBI AND GD3 SUPPORT YOUR PROGRAMS?

Find out more about GD3, please visit http://gd3services.com/

Contact: Jonathan A. Geller, MS
Business Development Manager
jgeller@genesisbiotechgroup.com
(888) 994-4870 or (408) 738-9266

NEED TO CONDUCT A STUDY?

Click here and check out our website.
www.compbio.com

Comparative Biosciences, Inc.
786 Lucerne Drive - Sunnyvale, CA 94085 - Telephone 408-738-9266